

# SBIO

## ALPS Medical Breakthroughs ETF

### Analyst Report

SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.

### ESG Themes and Scores

4.13/10

ESG Rate

2.42%

Global Percentile

2.55%

Peer Percentile

### Performance Data

	SBIO	ETF Database Category Average	Factset Segment Average
1 Month	-2.10%	-2.57%	-0.09%
3 Month	9.16%	3.82%	11.08%
YTD Return	-1.82%	-0.20%	3.47%
1 Year Return	56.76%	17.74%	31.22%
3 Year Return	18.48%	6.30%	10.58%
5 Year Return	-3.08%	-0.37%	0.06%

### Top 5 Holdings

Symbol	Holding	% Assets
KYMR	Kymera Therapeutics, Inc.	4.01%
ALKS	Alkermes Public Limited Company	3.70%
MIRM	Mirum Pharmaceuticals, Inc.	3.32%
CELC	Celcuity Inc.	3.21%
GPCR	Structure Therapeutics, Inc. Sponsored ADR	3.08%

### Vitals

Issuer	SS&C
Brand	ALPS
Structure	ETF
Expense Ratio	0.50%
Inception	Dec 31, 2014
Index Tracked	S-Network Medical Breakthroughs Index

### ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Small-Cap
Asset Class Style	Growth
Region (General)	North America
Region (Specific)	U.S.

### FactSet Classifications

Segment	Equity: U.S. Biotechnology
Category	Sector
Focus	Health Care
Niche	Biotechnology
Strategy	Fundamental
Weighting	Market Cap

